🇭🇰 港交所REMEGENDoubao · 实盘不做把握 9/10不做原因:标的无直接敞口
北京时间·🕒 发布 17:26:00时区推断·⟳ 抓取 17:27:17·⚡ 决策 10-14 21:36:52 +4h09m·12.9 天前
荣昌生物使用闲置自有资金3.7亿元认购浦发银行结构性存款，属常规现金管理披露
这是biotech用闲置自有资金做的保本型短期结构性存款，董事会早已授权25亿元额度，本次3.7亿元仅是额度内滚动操作并因12个月累计比率超5%而履行披露义务；不涉及融资、摊薄、订单、管线进展或盈利指引变化，对公司价值无可交易的增量影响，交易对手浦发银行亦不受影响。
📄 原文REMEGEN↗ 原文
DISCLOSEABLE TRANSACTION - PURCHASE OF WEALTH MANAGEMENT PRODUCTS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the con…
不做 荣昌生物(H股)（09995.HK）
闲置自有资金认购保本结构性存款属25亿元授权额度内常规现金管理，仅触发须予披露交易门槛，对管线、收入、盈利与估值无可交易的增量影响，无edge
不做 荣昌生物(A股科创板)（688331.SH）
同一现金管理事项，A/H基本面一致，不构成方向性催化，无交易价值
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
荣昌生物以3.7亿元闲置自有资金认购浦发银行保本结构性存款，属25亿元授权额度内的常规现金管理，仅触发港股须予披露交易门槛，对基本面和估值无实质影响，无交易机会。
🔎 新鲜度:最早出现 2026-10-14 · 扩散 low · price-in 风险 low ↗
主要风险
- 若市场将Biotech大额买理财解读为研发投入放缓或现金使用保守，或带来轻微情绪扰动，但公告本身不构成净损害事实
- 结构性存款浮动收益部分挂钩欧元兑美元汇率，但本金保障、金额有限，收益波动对盈利无实质影响
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-10-14 · 影响 none
公告明确资金为闲置自有资金、非募集资金变相补流，亦无配股/可转债/减持等条款；不构成利好也不构成隐藏利空
检索:荣昌生物 现金管理 理财 是否伴随 融资 配售 减持 管线 利空 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不改变结论；该类现金管理披露对股价无可测的方向性影响，直接AVOID
方向:无可比先例亦无必要：上市公司闲置资金买保本理财是高度程式化事项，历史上基本不产生方向性股价反应
涨幅量级:不适用，无ENTER腿，不需用先例校准幅度
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`remegen 9995 spdb wealth management product purchase | 荣昌生物 利多多 对公结构性存款 99jg4360 99jg4361 | 荣昌生物 浦发银行 结构性存款 理财产品 3.7亿`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 13,538 字
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.
RemeGen Co., Ltd.*
榮昌生物製藥(煙台)股份有限公司
(A joint stock company incorporated in the People ’s Republic of China with limited liability)
(Stock Code: 9995)
DISCLOSEABLE TRANSACTION
PURCHASE OF WEALTH MANAGEMENT PRODUCTS
PURCHASE OF WEALTH MANAGEMENT PRODUCTS
At the 36th meeting held by the second session of the Board on March 27, 2026, (1) a resolution
regarding cash management using self-owned funds was considered and approved, pursuant to
which the Company may purchase wealth management products using part of idle self-owned
funds of not more than RMB2,500.0 million; and (2) a resolution regarding cash management
using idle raised proceeds was considered and approved, pursuant to which the Company may
purchase principal-guaranteed wealth management products using part of idle raised proceeds
from A shares of not more than RMB80.0 million.
As disclosed in the announcement of the Company dated May 13, 2026, (1) on May 6, 2026,
the Company entered into the SPDB Wealth Management Product Agreement No. 5 with SPDB
Yantai Branch, pursuant to which the Company agreed to purchase wealth management product
of an amount of RMB200.0 million from SPDB Yantai Branch using idle self-owned funds;
and (2) on May 13, 2026, the Company entered into the SPDB Wealth Management Product
Agreement No. 7 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase
wealth management product of an amount of RMB100.0 million from SPDB Yantai Branch
using idle self-owned funds.
The Board announces that, on October 14, 2026, the Company further entered into with SPDB
Yantai Branch (1) the SPDB Wealth Management Product Agreement No. 12, pursuant to which
the Company agreed to purchase wealth management product of an amount of RMB70.0 million
from SPDB Yantai Branch using idle self-owned funds; and (2) the SPDB Wealth Management
Product Agreement No. 13, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB300.0 million from SPDB Yantai Branch using idle
self-owned funds.
1
LISTING RULES IMPLICATIONS
As the Company entered into (1) the SPDB Wealth Management Product Agreement No. 5 with
SPDB Yantai Branch on May 6, 2026, (2) the SPDB Wealth Management Product Agreement
No. 7 with SPDB Yantai Branch on May 13, 2026, and still holds the wealth management
products under such agreements, and the transactions contemplated under (1) the SPDB Wealth
Management Product Agreement No. 5, (2) the SPDB Wealth Management Product Agreement
No. 7, (3) the SPDB Wealth Management Product Agreement No. 12 and (4) the SPDB Wealth
Management Product Agreement No. 13 are conducted with the same bank and are of similar
nature within a 12-month period, for the purpose of calculating the relevant percentage ratios
under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if
they were one transaction with the said bank.
As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules)
in respect of the SPDB Wealth Management Product Agreements exceeds 5% but all of the
applicable percentage ratios are less than 25%, the purchase of wealth management products
under the SPDB Wealth Management Product Agreements therefore constitutes a discloseable
transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting
and announcement requirements under the Listing Rules.
BACKGROUND
On May 6, 2026, the Company entered into the SPDB Wealth Management Product Agreement
No. 5 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB200.0 million from SPDB Yantai Branch using idle
self-owned funds.
On May 13, 2026, the Company entered into the SPDB Wealth Management Product Agreement
No. 7 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB100.0 million from SPDB Yantai Branch using idle
self-owned funds.
The Board announces that, on October 14, 2026, the Company further entered into with SPDB
Yantai Branch (1) the SPDB Wealth Management Product Agreement No. 12, pursuant to which
the Company agreed to purchase wealth management product of an amount of RMB70.0 million
from SPDB Yantai Branch using idle self-owned funds; and (2) the SPDB Wealth Management
Product Agreement No. 13, pursuant to which the Company agreed to purchase wealth management
product of an amount of RMB300.0 million from SPDB Yantai Branch using idle self-owned
funds.
2
SPDB WEALTH MANAGEMENT PRODUCT AGREEMENTS
The principal terms of the SPDB Wealth Management Product Agreement No. 12 are set out as
follows:
Name of product
:
Liduoduo Corporate Stable Profit 99JG4360 (Three-Tier Bullish)
RMB Corporate Structured Deposit (利多多公司穩利 99JG4360
期(三層看漲)人民幣對公結構性存款)
Type of product
:
Principal-guaranteed with floating income
Linked target
:
EUR-USD exchange rate
Principal amount
:
RMB70.0 million
Validity period of
product
:
69 days
Effective date of
product
:
October 14, 2026
Expiry date of
product
:
December 23, 2026
Expected annualized
yield rate
:
0.7% or 1.75% or 1.95%
Right of early
termination
:
SPDB Yantai Branch has the right to early terminate the
agreement.
Investment scope
:
The proceeds from the sales of this structured deposit product
will be nominal principal, the capital costs of which will be used
to enter into transactions with counterparty to make investment
in financial derivatives linked to the counterparty’s investment
income and the EUR-USD spot rate.
The principal terms of the SPDB Wealth Management Product Agreement No. 13 are set out as
follows:
Name of product
:
Liduoduo Corporate Stable Profit 99JG4361 (Three-Tier Bullish)
RMB Corporate Structured Deposit (利多多公司穩利 99JG4361
期(三層看漲)人民幣對公結構性存款)
Type of product
:
Principal-guaranteed with floating income
Linked target
:
EUR-USD exchange rate
Principal amount
:
RMB300.0 million
Validity period of
product
:
30 days
3
Effective date of
product
:
October 14, 2026
Expiry date of
product
:
November 13, 2026
Expected annualized
yield rate
:
0.7% or 1.75% or 1.95%
Right of early
termination
:
SPDB Yantai Branch has the right to early terminate the
agreement.
Investment scope
:
The proceeds from the sales of this structured deposit product
will be nominal principal, the capital costs of which will be used
to enter into transactions with counterparty to make investment
in financial derivatives linked to the counterparty’s investment
income and the EUR-USD spot rate.
The terms of the SPDB Wealth Management Product Agreements were determined upon arm’s
length negotiations between the parties.
INFORMATION ON THE PARTIES
The Company is a commercial-ready biopharmaceutical company committed to the discovery,
development and commercialization of innovative and differentiated biologics for the treatment of
autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.
SPDB is a bank incorporated in the PRC, the shares of which are listed on the Shanghai Stock
Exchange (stock code: 600000). The principal businesses of SPDB are providing corporate and
personal banking services, conducting treasury business, and providing asset management and
other financial services. SPDB Yantai Branch is a branch of SPDB.
To the best knowledge, information and belief of the Directors having made all reasonable
enquiries, SPDB Yantai Branch, SPDB and their ultimate substantial beneficial owners as publicly
disclosed by SPDB are third parties independent from the Company and its connected persons.
REASONS AND BENEFITS FOR ENTERING INTO THE SPDB WEALTH MANAGEMENT
PRODUCT AGREEMENTS
On the premise of strictly controlling investment risks, the Company intends to fully revitalize idle
self-owned funds and improve capital utilization efficiency by deploying and managing idle funds
through bank wealth management products. The allocated low-to-medium risk products feature
overall controllable risks and yields higher than those of bank time deposits for the same period,
which can effectively boost the investment returns on idle funds.
The Directors consider that the terms of the SPDB Wealth Management Product Agreements and
the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or
better in the ordinary course of business of the Group, and are in the interests of the Company and
its Shareholders as a whole.
4
LISTING RULES IMPLICATIONS
As the Company entered into (1) the SPDB Wealth Management Product Agreement No. 5 with
SPDB Yantai Branch on May 6, 2026, (2) the SPDB Wealth Management Product Agreement No.
7 with SPDB Yantai Branch on May 13, 2026, and still holds the wealth management products
under such agreements, and the transactions contemplated under (1) the SPDB Wealth Management
Product Agreement No. 5, (2) the SPDB Wealth Management Product Agreement No. 7, (3) the
SPDB Wealth Management Product Agreement No. 12 and (4) the SPDB Wealth Management
Product Agreement No. 13 are conducted with the same bank and are of similar nature within a
12-month period, for the purpose of calculating the relevant percentage ratios under Rule 14.22
of the Listing Rules, these transactions shall be aggregated in each case as if they were one
transaction with the said bank.
As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in
respect of the SPDB Wealth Management Product Agreements exceeds 5% but all of the applicable
percentage ratios are less than 25%, the purchase of wealth management products under the SPDB
Wealth Management Product Agreements therefore constitutes a discloseable transaction of the
Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement
requirements under the Listing Rules.
DEFINITIONS
Unless the context otherwise requires, the following terms used herein have the following
meanings:
“Board”
the board of Directors
“Company”
RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a joint stock
company incorporated in the PRC with limited liability, the H shares and
A shares of which are listed on the Main Board of the Stock Exchange
(stock code: 9995) and the Science and Technology Innovation Board of
the Shanghai Stock Exchange (stock code: 688331), respectively
“connected person”
has the meaning ascribed to it under the Listing Rules
“Director(s)”
the director(s) of the Company
“EUR”
Euro, the lawful currency of the European Union
“Group”
the Company and its subsidiaries
“Hong Kong”
the Hong Kong Special Administrative Region of the People ’s Republic of
China
“Listing Rules”
the Rules Governing the Listing of Securities on the Stock Exchange
5
“PRC” or “China”
the People ’ s Republic of China excluding, for the purpose of this
announcement, Hong Kong, the Macau Special Administrative Region of
the People’s Republic of China and Taiwan
“RMB”
Renminbi, the lawful currency of the PRC
“Shareholder(s)”
holder(s) of the shares of the Company
“SPDB”
Shanghai Pudong Development Bank Co., Ltd., a bank incorporated in the
PRC
“SPDB Wealth
SPDB Wealth Management Product Agreement No. 5, SPDB Wealth
Management Product Management Product Agreement No. 7, SPDB Wealth Management
Agreements”
Product Agreement No. 12, and SPDB Wealth Management Product
Agreement No. 13
“SPDB Wealth
the wealth management product agreement entered into between the
Management Product Company and SPDB Yantai Branch dated May 6, 2026 in relation to the
Agreement No. 5”
purchase of wealth management product in the amount of RMB200.0
million
“SPDB Wealth
the wealth management product agreement entered into between the
Management Product Company and SPDB Yantai Branch dated May 13, 2026 in relation to
Agreement No. 7”
the purchase of wealth management product in the amount of RMB100.0
million
“SPDB Wealth
the wealth management product agreement entered into between the
Management Product Company and SPDB Yantai Branch dated October 14, 2026 in relation to
Agreement No. 12” the purchase of wealth management product in the amount of RMB70.0
million
“SPDB Wealth
the wealth management product agreement entered into between the
Management Product Company and SPDB Yantai Branch dated October 14, 2026 in relation to
Agreement No. 13” the purchase of wealth management product in the amount of RMB300.0
million
“SPDB Yantai Branch” Yantai Branch of Shanghai Pudong Development Bank Co., Ltd.
6
“Stock Exchange”
The Stock Exchange of Hong Kong Limited
“USD”
United States dollar, the lawful currency of the United States of America
“%”
percent
By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and Executive Director
Yantai, the PRC
October 14, 2026
As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin,
Mr. Wen Qingkai, Ms. Fang Michelle Yi and Mr. Wang Yuxiao as the executive Directors, Dr.
Wang Liqiang as the non-executive Director, and Mr. Song Xiliang, Mr. Huang Guobin and Mr.
Chen Yunjin as the independent non-executive Directors.
* For identification purpose only
7
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.
RemeGen Co., Ltd.*
榮昌生物製藥(煙台)股份有限公司
(A joint stock company incorporated in the People ’s Republic of China with limited liability)
(Stock Code: 9995)
DISCLOSEABLE TRANSACTION
PURCHASE OF WEALTH MANAGEMENT PRODUCTS
PURCHASE OF WEALTH MANAGEMENT PRODUCTS
At the 36th meeting held by the second session of the Board on March 27, 2026, (1) a resolution
regarding cash management using self-owned funds was considered and approved, pursuant to
which the Company may purchase wealth management products using part of idle self-owned
funds of not more than RMB2,500.0 million; and (2) a resolution regarding cash management
using idle raised proceeds was considered and approved, pursuant to which the Company may
purchase principal-guaranteed wealth management products using part of idle raised proceeds
from A shares of not more than RMB80.0 million.
As disclosed in the announcement of the Company dated May 13, 2026, (1) on May 6, 2026,
the Company entered into the SPDB Wealth Management Product Agreement No. 5 with SPDB
Yantai Branch, pursuant to which the Company agreed to purchase wealth management product
of an amount of RMB200.0 million from SPDB Yantai Branch using idle self-owned funds;
and (2) on May 13, 2026, the Company entered into the SPDB Wealth Management Product
Agreement No. 7 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase
wealth management product of an amount of RMB100.0 million from SPDB Yantai Branch
using idle self-owned funds.
The Board announces that, on October 14, 2026, the Company further entered into with SPDB
Yantai Branch (1) the SPDB Wealth Management Product Agreement No. 12, pursuant to which
the Company agreed to purchase wealth management product of an amount of RMB70.0 million
from SPDB Yantai Branch using idle self-owned funds; and (2) the SPDB Wealth Management
Product Agreement No. 13, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB300.0 million from SPDB Yantai Branch using idle
self-owned funds.
1
LISTING RULES IMPLICATIONS
As the Company entered into (1) the SPDB Wealth Management Product Agreement No. 5 with
SPDB Yantai Branch on May 6, 2026, (2) the SPDB Wealth Management Product Agreement
No. 7 with SPDB Yantai Branch on May 13, 2026, and still holds the wealth management
products under such agreements, and the transactions contemplated under (1) the SPDB Wealth
Management Product Agreement No. 5, (2) the SPDB Wealth Management Product Agreement
No. 7, (3) the SPDB Wealth Management Product Agreement No. 12 and (4) the SPDB Wealth
Management Product Agreement No. 13 are conducted with the same bank and are of similar
nature within a 12-month period, for the purpose of calculating the relevant percentage ratios
under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if
they were one transaction with the said bank.
As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules)
in respect of the SPDB Wealth Management Product Agreements exceeds 5% but all of the
applicable percentage ratios are less than 25%, the purchase of wealth management products
under the SPDB Wealth Management Product Agreements therefore constitutes a discloseable
transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting
and announcement requirements under the Listing Rules.
BACKGROUND
On May 6, 2026, the Company entered into the SPDB Wealth Management Product Agreement
No. 5 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB200.0 million from SPDB Yantai Branch using idle
self-owned funds.
On May 13, 2026, the Company entered into the SPDB Wealth Management Product Agreement
No. 7 with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth
management product of an amount of RMB100.0 million from SPDB Yantai Branch using idle
self-owned funds.
The Board announces that, on October 14, 2026, the Company further entered into with SPDB
Yantai Branch (1) the SPDB Wealth Management Product Agreement No. 12, pursuant to which
the Company agreed to purchase wealth management product of an amount of RMB70.0 million
from SPDB Yantai Branch using idle self-owned funds; and (2) the SPDB Wealth Management
Product Agreement No. 13, pursuant to which the Company agreed to purchase wealth management
product of an amount of RMB300.0 million from SPDB Yantai Branch using idle self-owned
funds.
2
SPDB WEALTH MANAGEMENT PRODUCT AGREEMENTS
The principal terms of the SPDB Wealth Management Product Agreement No. 12 are set out as
follows:
Name of product
:
Liduoduo Corporate Stable Profit 99JG4360 (Three-Tier Bullish)
RMB Corporate Structured Deposit (利多多公司穩利 99JG4360
期(三層看漲)人民幣對公結構性存款)
Type of product
:
Principal-guaranteed with floating income
Linked target
:
EUR-USD exchange rate
Principal amount
:
RMB70.0 million
Validity period of
product
:
69 days
Effective date of
product
:
October 14, 2026
Expiry date of
product
:
December 23, 2026
Expected annualized
yield rate
:
0.7% or 1.75% or 1.95%
Right of early
termination
:
SPDB Yantai Branch has the right to early terminate the
agreement.
Investment scope
:
The proceeds from the sales of this structured deposit product
will be nominal principal, the capital costs of which will be used
to enter into transactions with counterparty to make investment
in financial derivatives linked to the counterparty’s investment
income and the EUR-USD spot rate.
The principal terms of the SPDB Wealth Management Product Agreement No. 13 are set out as
follows:
Name of product
:
Liduoduo Corporate Stable Profit 99JG4361 (Three-Tier Bullish)
RMB Corporate Structured Deposit (利多多公司穩利 99JG4361
期(三層看漲)人民幣對公結構性存款)
Type of product
:
Principal-guaranteed with floating income
Linked target
:
EUR-USD exchange rate
Principal amount
:
RMB300.0 million
Validity period of
product
:
30 days
3
Effective date of
product
:
October 14, 2026
Expiry date of
product
:
November 13, 2026
Expected annualized
yield rate
:
0.7% or 1.75% or 1.95%
Right of early
termination
:
SPDB Yantai Branch has the right to early terminate the
agreement.
Investment scope
:
The proceeds from the sales of this structured deposit product
will be nominal principal, the capital costs of which will be used
to enter into transactions with counterparty to make investment
in financial derivatives linked to the counterparty’s investment
income and the EUR-USD spot rate.
The terms of the SPDB Wealth Management Product Agreements were determined upon arm’s
length negotiations between the parties.
INFORMATION ON THE PARTIES
The Company is a commercial-ready biopharmaceutical company committed to the discovery,
development and commercialization of innovative and differentiated biologics for the treatment of
autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.
SPDB is a bank incorporated in the PRC, the shares of which are listed on the Shanghai Stock
Exchange (stock code: 600000). The principal businesses of SPDB are providing corporate and
personal banking services, conducting treasury business, and providing asset management and
other financial services. SPDB Yantai Branch is a branch of SPDB.
To the best knowledge, information and belief of the Directors having made all reasonable
enquiries, SPDB Yantai Branch, SPDB and their ultimate substantial beneficial owners as publicly
disclosed by SPDB are third parties independent from the Company and its connected persons.
REASONS AND BENEFITS FOR ENTERING INTO THE SPDB WEALTH MANAGEMENT
PRODUCT AGREEMENTS
On the premise of strictly controlling investment risks, the Company intends to fully revitalize idle
self-owned funds and improve capital utilization efficiency by deploying and managing idle funds
through bank wealth management products. The allocated low-to-medium risk products feature
overall controllable risks and yields higher than those of bank time deposits for the same period,
which can effectively boost the investment returns on idle funds.
The Directors consider that the terms of the SPDB Wealth Management Product Agreements and
the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or
better in the ordinary course of business of the Group, and are in the interests of the Company and
its Shareholders as a whole.
4
LISTING RULES IMPLICATIONS
As the Company entered into (1) the SPDB Wealth Management Product Agreement No. 5 with
SPDB Yantai Branch on May 6, 2026, (2) the SPDB Wealth Management Product Agreement No.
7 with SPDB Yantai Branch on May 13, 2026, and still holds the wealth management products
under such agreements, and the transactions contemplated under (1) the SPDB Wealth Management
Product Agreement No. 5, (2) the SPDB Wealth Management Product Agreement No. 7, (3) the
SPDB Wealth Management Product Agreement No. 12 and (4) the SPDB Wealth Management
Product Agreement No. 13 are conducted with the same bank and are of similar nature within a
12-month period, for the purpose of calculating the relevant percentage ratios under Rule 14.22
of the Listing Rules, these transactions shall be aggregated in each case as if they were one
transaction with the said bank.
As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in
respect of the SPDB Wealth Management Product Agreements exceeds 5% but all of the applicable
percentage ratios are less than 25%, the purchase of wealth management products under the SPDB
Wealth Management Product Agreements therefore constitutes a discloseable transaction of the
Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement
requirements under the Listing Rules.
DEFINITIONS
Unless the context otherwise requires, the following terms used herein have the following
meanings:
“Board”
the board of Directors
“Company”
RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a joint stock
company incorporated in the PRC with limited liability, the H shares and
A shares of which are listed on the Main Board of the Stock Exchange
(stock code: 9995) and the Science and Technology Innovation Board of
the Shanghai Stock Exchange (stock code: 688331), respectively
“connected person”
has the meaning ascribed to it under the Listing Rules
“Director(s)”
the director(s) of the Company
“EUR”
Euro, the lawful currency of the European Union
“Group”
the Company and its subsidiaries
“Hong Kong”
the Hong Kong Special Administrative Region of the People ’s Republic of
China
“Listing Rules”
the Rules Governing the Listing of Securities on the Stock Exchange
5
“PRC” or “China”
the People ’ s Republic of China excluding, for the purpose of this
announcement, Hong Kong, the Macau Special Administrative Region of
the People’s Republic of China and Taiwan
“RMB”
Renminbi, the lawful currency of the PRC
“Shareholder(s)”
holder(s) of the shares of the Company
“SPDB”
Shanghai Pudong Development Bank Co., Ltd., a bank incorporated in the
PRC
“SPDB Wealth
SPDB Wealth Management Product Agreement No. 5, SPDB Wealth
Management Product Management Product Agreement No. 7, SPDB Wealth Management
Agreements”
Product Agreement No. 12, and SPDB Wealth Management Product
Agreement No. 13
“SPDB Wealth
the wealth management product agreement entered into between the
Management Product Company and SPDB Yantai Branch dated May 6, 2026 in relation to the
Agreement No. 5”
purchase of wealth management product in the amount of RMB200.0
million
“SPDB Wealth
the wealth management product agreement entered into between the
Management Product Company and SPDB Yantai Branch dated May 13, 2026 in relation to
Agreement No. 7”
the purchase of wealth management product in the amount of RMB100.0
million
“SPDB Wealth
the wealth management product agreement entered into between the
Management Product Company and SPDB Yantai Branch dated October 14, 2026 in relation to
Agreement No. 12” the purchase of wealth management product in the amount of RMB70.0
million
“SPDB Wealth
the wealth management product agreement entered into between the
Management Product Company and SPDB Yantai Branch dated October 14, 2026 in relation to
Agreement No. 13” the purchase of wealth management product in the amount of RMB300.0
million
“SPDB Yantai Branch” Yantai Branch of Shanghai Pudong Development Bank Co., Ltd.
6
“Stock Exchange”
The Stock Exchange of Hong Kong Limited
“USD”
United States dollar, the lawful currency of the United States of America
“%”
percent
By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and Executive Director
Yantai, the PRC
October 14, 2026
As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin,
Mr. Wen Qingkai, Ms. Fang Michelle Yi and Mr. Wang Yuxiao as the executive Directors, Dr.
Wang Liqiang as the non-executive Director, and Mr. Song Xiliang, Mr. Huang Guobin and Mr.
Chen Yunjin as the independent non-executive Directors.
* For identification purpose only
7
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
2fb7327b23· 2026-10-14 21:36 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前